A cutting-edge cure or CRISPR catastrophe? That’s the question facing regulators as a revolutionary new gene editing treatment for sickle cell disease seeks approval.
The therapy, called exa-cel, is a new technology that would precisely edit a patient’s DNA. But in recent documents, the U.S. Food and Drug Administration has sounded the alarm about potential unintended edits that could have far-reaching health consequences.
